Aprea Therapeutics (NASDAQ:APRE) Given “Outperform” Rating at Wedbush

Aprea Therapeutics (NASDAQ:APRE)‘s stock had its “outperform” rating reaffirmed by research analysts at Wedbush in a report released on Tuesday,Benzinga reports. They currently have a $7.00 price target on the stock.

APRE has been the topic of several other research reports. Zacks Research upgraded shares of Aprea Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, February 16th. Weiss Ratings restated a “sell (e+)” rating on shares of Aprea Therapeutics in a research report on Wednesday, January 21st. Finally, HC Wainwright cut their target price on shares of Aprea Therapeutics from $4.00 to $1.20 and set a “buy” rating for the company in a research note on Tuesday. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $4.10.

Aprea Therapeutics Stock Up 0.7%

NASDAQ:APRE traded up $0.01 on Tuesday, reaching $0.74. 150,600 shares of the company’s stock traded hands, compared to its average volume of 2,300,393. The firm has a market cap of $8.52 million, a PE ratio of -0.38 and a beta of 1.42. The stock has a 50-day simple moving average of $0.76 and a 200-day simple moving average of $1.05. Aprea Therapeutics has a 12 month low of $0.55 and a 12 month high of $2.30.

Aprea Therapeutics (NASDAQ:APRE) last released its earnings results on Monday, March 16th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.38) by $0.06. The firm had revenue of $0.00 million during the quarter. Aprea Therapeutics had a negative return on equity of 96.33% and a negative net margin of 4,405.59%. On average, equities analysts anticipate that Aprea Therapeutics will post -2.55 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Aprea Therapeutics stock. Jane Street Group LLC purchased a new position in Aprea Therapeutics, Inc. (NASDAQ:APRE) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 46,621 shares of the company’s stock, valued at approximately $40,000. Jane Street Group LLC owned approximately 0.67% of Aprea Therapeutics at the end of the most recent quarter. 34.19% of the stock is currently owned by hedge funds and other institutional investors.

About Aprea Therapeutics

Aprea Therapeutics is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies that restore tumor suppressor function in cancers driven by TP53 mutations. The company’s lead investigational agent, eprenetapopt (APR-246), is designed to convert mutant p53 protein into a form that induces programmed cell death in malignant cells. Aprea’s research focuses on hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as solid tumors harboring TP53 mutations.

Eprenetapopt has advanced through multiple clinical trials, including pivotal studies assessing its efficacy in combination with hypomethylating agents for patients with MDS.